Pharmacological basis for duration of effect: Formoterol and salmeterol versus short-acting beta(2)-adrenoceptor agonists

被引:0
|
作者
Linden, A
Rabe, KF
Lofdahl, CG
机构
[1] GOTHENBURG UNIV, SAHLGRENS HOSP, DIV PULM MED, S-41345 GOTHENBURG, SWEDEN
[2] KRANKENHAUS GROSSHANSDORF, LANDESVERSICHERUNGANSTALT HAMBURG, ZENTRUM PNEUMOL & THORAXCHIRURG, D-22927 GROSSHANSDORF, GERMANY
关键词
airway smooth-muscle relaxation; beta(2)-adrenoceptor agonists; bronchodilator; duration of action; exosite; formoterol; microkinetic diffusion; salmeterol; BETA-ADRENOCEPTOR AGONISTS; AIRWAY SMOOTH-MUSCLE; GUINEA-PIG TRACHEA; BETA-2-ADRENOCEPTOR AGONIST; FUNCTIONAL ANTAGONISM; SALBUTAMOL; RELEASE; BAMBUTEROL; INVITRO; ASTHMA;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The mechanisms behind the long duration of bronchodilating action of the beta(2)-adrenoceptor agonists formoterol and salmeterol are only partially understood, This review compares pharmacological characteristics of long-acting versus short-acting beta(2)-adrenoceptor agonists in human and animal airways. Based upon the reviewed evidence, it is concluded that for beta(2)-adrenoceptor agonists, long duration of action may depend upon several factors, Both formoterol and salmeterol display a higher lipophilicity and have a higher affinity, selectivity, and potency than most short-acting agonists at the beta(2)-adrenoceptor. Of these factors, lipophilicity may prove to be one of the most important ones by determining the amount of drug entering into the cell membrane in the vicinity of the beta(2)-adrenoceptor. However, the receptor affinity, maximal relaxant effect (efficacy or intrinsic activity), potency, and receptor selectivity may also be of importance in determining how much beta(2)-adrenoceptor agonist must remain at the receptor for sustained action.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 50 条
  • [31] Long- and short-acting beta(2)-adrenergic agonists - Effects on airway function in patients with asthma
    Busse, WW
    ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (14) : 1514 - 1520
  • [32] 2 NEW DOPAMINE AGONISTS THAT ARE LONG-ACTING INVIVO BUT SHORT-ACTING INVITRO
    GROSSMAN, A
    YEO, T
    DELITALA, G
    HATHWAY, NR
    BESSER, GM
    CLINICAL ENDOCRINOLOGY, 1980, 13 (06) : 595 - 599
  • [33] ROSIGLITAZONE OVERCOMES RESISTANCE TO BOTH SHORT-ACTING AND LONG-ACTING β2-ADRENOCEPTOR AGONISTS IN SMALL AIRWAYS IN MOUSE LUNG SLICES
    Bourke, J. E.
    Esposito, J.
    Cheong, J. N.
    Kam, N. M.
    Bailey, S.
    Donovan, C.
    RESPIROLOGY, 2012, 17 : 13 - 13
  • [34] Overreliance link between asthmatic subjects and short-acting β2 agonists
    Nannini, Luis J.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 50 : 80 - 81
  • [35] Is it time to move away from short-acting beta-agonists in asthma management?
    Martin, Matthew J.
    Harrison, Tim W.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (04)
  • [36] The duration of action of non-beta(2)-adrenoceptor mediated responses to salmeterol
    Nials, AT
    Coleman, RA
    Johnson, M
    Vardey, CJ
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (05) : 961 - 967
  • [37] Effect of short-acting inhaler β2-agonists on serum cardiac troponin in wheezy infant
    Tasar, MA
    Bostanci, I
    Atli, Ö
    Dallar, Y
    ALLERGY AND ASTHMA PROCEEDINGS, 2005, 26 (06) : 477 - 482
  • [38] Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting β2-agonists alone
    Calhoun, WJ
    Nelson, HS
    Nathan, RA
    Pepsin, PJ
    Kalberg, C
    Emmett, A
    Rickard, KA
    Dorinsky, P
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (05) : 759 - 763
  • [39] Fluticasone propionate/salmeterol Diskus® combination product provides superior asthma control compared with fluticasone propionate and salmeterol alone in patients previously receiving PRN short-acting beta2-agonists alone
    Rosenthal, RR
    Blake, K
    Strek, M
    Lange, M
    House, KW
    Vandermeer, AK
    Shah, TP
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S245 - S245
  • [40] Electronic medication monitoring versus self-reported use of inhaled corticosteroids and short-acting beta2-agonists in uncontrolled asthma
    Mosnaim, Giselle S.
    Stempel, David A.
    Gonzalez, Candy
    Adams, Brittney
    BenIsrael-Olive, Naomi
    Gondalia, Rahul
    Kaye, Leanne
    Shalowitz, Madeleine
    Szefler, Stanley
    JOURNAL OF ASTHMA, 2022, 59 (10) : 2024 - 2027